利妥昔单抗联合化疗治疗B细胞非霍奇金淋巴瘤合并乙肝病毒感染的临床观察被引量：2

Clinical observation of Rituximab combined with chemotherapy in the treatment of B cell non-Hodgkin′s lymphoma patients complicated with HBV infection

下载PDF

导出

摘要目的探讨利妥昔单抗联合化疗(R-CHOP方案)治疗非霍奇金淋巴瘤(NHL)合并乙型肝炎病毒(HBV)携带者的安全性和有效性。方法将2004年1月至2010年1月收治的32例B细胞NHL患者分为2组,A组(n=12)为感染HBV的患者,B组(n=20)为非感染HBV患者。A、B组均接受R-CHOP方案化疗4～6周期。A组化疗前应用拉米夫定抗病毒治疗1周。观察两组疗效、肝功能异常发生率。结果A组CR率为83.33%,B组CR率为85.00%(P>0.05)。A组Ⅰ～Ⅱ级肝功能损害发生率为16.67%,B组15.00%(P>0.05),两组差异无统计学意义。两组患者中均未发生HBV再激活。结论感染HBV的NHL患者用R-CHOP方案治疗及在化疗前预防性、足疗程的抗病毒治疗,可降低HBV再激活风险,减少肝功能损害。 Objective To study the efficacy and safety of rituximab combined with chemotherapy （ R-CHOP regimen） in the treatment of non-Hodgkin＇s lymphoma （NHL） patients complicated with HBV infection. Methods 32 B-cell NHL patients were divided into two groups, group A （patients with HBV infection, n = 12）, and group B （patients without HBV infection, n = 20）. All of them were treated with R-CHOP regimen for four to six cycles from 2004 to 2010 and the group A was treated with lamivudine antiviral treatment before R-CHOP treatment. The duration of liver dysfunction and the efficacy of the treatment regimen were observed. Results The complete response rate was 83.3 % in group A, while 85.0% in group B （ P 〉 0.05 ）. Ⅰ～Ⅱ class live function impairment was 16.7% in group A, and 15.0% in group B （P 〉 0.05 ）. Both two groups had not hepatitis B reactivation occurred. Conclusion NHL patients complicated with HBV infection, when treated with preventive anti-virus therapy before chemotherapy can decrease hepatitis B reactivation.

作者李云涛石琳熙

机构地区昆明医学院第一附属医院血液科昆明医学院微生物免疫教研室

出处《内科》 2011年第5期406-408,共3页 Internal Medicine

关键词乙型肝炎病毒非霍奇金淋巴瘤利妥昔单抗化学疗法 Hepatitis B virus Non-Hodgkin＇s lymphoma Rituximab Chemotherapy

分类号 R512.62 [医药卫生—内科学] R551.2 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献14

1Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [ M ]. Lyon : IARC Press,2008 : 267 - 368.
2Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy [ J ]. Hepatology, 2006,43 ( 2 ) :209 - 220.
3Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab [ J ]. N Engl J Med, 2001,344 ( 1 ) :68 - 69.
4Domingo-Domenech E, Gonzadez-Barca E, Estany C, et al. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas [ J ]. Haematologica, 2002,87 (11 ) : 1229 - 1230.
5Dai MS, Chao TY, Kao WY, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudinein lymphoma patientstreated with rituximab plus CHOP[ J ]. Ann Hematol,2004,83 (12) : 769 - 774.
6Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositivecancer patients undergoing cytotoxic chemotherapy [ J ]. J Clin 0ncol,2004,22 (5) :927 - 934.
7Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reativation due torituximab therapy in a patient with non-Hodgkin's lymphoma [ J]. Ann Hematol,2004,83( 1 ) :58 -60.
8Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin' s lymphoma: a randomized trial [ J ]. Hepatology,2008,47 ( 3 ) : 844 - 853.
9He YF, Li YH, Wang FH, et al. The effectiveness of lamivudine in preventing hepatitisB viral reactivation in rituximab-containing regimen for lymphoma [ J ]. Ann Hemato1,2008,87 ( 6 ) :481 - 485.
10Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab [J]. N Engl J Med,2001,344( 1 ) :68 -69.